Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
Described herein are genes whose expression are up-regulated or down-regulated in specific cancers. Related methods and compositions that can be used for diagnosis and treatment of those cancers are disclosed. Also described herein are methods that can be used to identify modulators of selected cancers.
1 . A method for determining the presence or absence of a pathological cell in a patient, said method comprising detecting a nucleic acid comprising a sequence at least 80% identical to a sequence as described in Tables 2A-68 in a biological sample from said patient, thereby determining the presence or absence of said pathological cell.
2 . The method of claim 1 , wherein:
a) said pathology is described in Table 1, including a cancer; and/or
b) said biological sample comprises isolated nucleic acids.
3 . The method of claim 1 , wherein said biological sample is tissue from an organ which is affected by said pathology of Table 1, including a cancer.
4 . The method of claim 2 , wherein said nucleic acids are mRNA
5 . The method of claim 2:
a) further comprising a step of amplifying nucleic acids before said step of detecting said nucleic acid; or
b) where said detecting is of a protein encoded by said nucleic acid.
6 . The method of claim 1 , wherein said nucleic acid comprises a sequence as described in Tables 2A-68.
7 . The method of claim 2 , wherein:
a) said detecting step is carried out by:
i) using a labeled nucleic acid probe;
ii) utilizing a biochip comprising a sequence at least 80% identical to a sequence as described in Tables 2A-68; or
iii) detecting a polypeptide encoded by said nucleic acid; or
b) said patient is:
i) undergoing a therapeutic regimen to treat said pathology of Table 1; or
ii) is suspected of having said pathology or cancer.
8 . An isolated nucleic acid molecule comprising a sequence as described in Tables 2A-68.
9 . The nucleic acid molecule of claim 8 , which is labeled.
10 . An expression vector comprising the nucleic acid of claim 8 .
11 . A host cell comprising the expression vector of claim 10 .
12 . An isolated polypeptide which is encoded by a nucleic acid molecule comprising a sequence as described in Tables 2A-68.
13 . An antibody that specifically binds a polypeptide of claim 12 .
14 . The antibody of claim 13:
a) conjugated to an effector component;
b) conjugated to a detectable label, including a fluorescent label, a radioisotope, or a cytotoxic chemical;
c) which is an antibody fragment; or
d) which is a humanized antibody.
15 . A method for specifically targeting a compound to a pathological cell in a patient, said method comprising administering to said patient an antibody of claim 13 , thereby providing said targetting.
16 . A method for determining the presence or absence of a pathological cell in a patient, said method comprising contacting a biological sample with an antibody of claim 13 .
17 . The method of claim 16 , wherein:
a) said antibody is conjugated to:
i) an effector component; or
ii) a fluorescent label; or
b) said biological sample is a blood, serum, urine, or stool sample.
18 . A method for identifying a compound that modulates a pathology-associated polypeptide, said method comprising the steps of:
a) contacting said compound with a pathology-associated polypeptide, said polypeptide encoded by a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as described in Tables 2A-68; and
b) determining the functional effect of said compound upon said polypeptide.
19 . A drug screening assay comprising the steps of:
a) administering a test compound to a mammal having a pathology of Table 1 or a cell isolated therefrom; and
b) comparing the level of gene expression of a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as described in Tables 2A-68 in a treated cell or mammal with the level of gene expression of said polynucleotide in a control cell or mammal, wherein a test compound that modulates said level of expression of the polynucleotide is a candidate for the treatment of said pathology.